Table 2 Evidence profiles
Certainty assessment | No of patients | Effect | Certainty | Importance | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | BCAA | placebo | Relative (95% CI) | Absolute (95% CI) | ||
Improvement of the disturbance of consciousness | ||||||||||||
4 | Randomized trials | Very seriousa | Not serious | Not serious | Seriousb | None | 59/102 (57.8%) | 45/99 (45.5%) | RR 1.26 (0.96 to 1.66) | 118 more per 1000 (from 18 fewer to 300 more) | ⨁◯◯◯ Very low | CRITICAL |
All-cause mortality | ||||||||||||
3 | Randomized trials | Very seriousc | Not serious | Not serious | Seriousb | None | 46/92 (50.0%) | 51/93 (54.8%) | RR 0.90 (0.70 to 1.16) | 55 fewer per 1000 (from 165 fewer to 88 more) | ⨁◯◯◯ Very low | CRITICAL |
Nausea | ||||||||||||
1 | Randomized trials | Seriousc | Not serious | Not serious | Seriousb | None | 3/35 (8.6%) | 3/35 (8.6%) | RR 1.00 (0.22 to 4.62) | 0 fewer per 1000 (from 67 fewer to 310 more) | ⨁⨁◯◯ Low | IMPORTANT |
Diarrhea | ||||||||||||
1 | Randomized trials | Seriousc | Not serious | Not serious | Seriousb | None | 4/35 (11.4%) | 5/35 (14.3%) | RR 0.80 (0.23 to 2.73) | 29 fewer per 1000 (from 110 fewer to 247 more) | ⨁⨁◯◯ Low | IMPORTANT |